Xencor (XNCR) Shares Gap Down to $30.98

Shares of Xencor Inc (NASDAQ:XNCR) gapped down before the market opened on Thursday . The stock had previously closed at $31.13, but opened at $30.98. Xencor shares last traded at $30.81, with a volume of 336403 shares.

XNCR has been the subject of a number of research reports. Cantor Fitzgerald initiated coverage on shares of Xencor in a report on Wednesday, November 29th. They set an “overweight” rating and a $33.00 target price for the company. BidaskClub upgraded shares of Xencor from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 24th. Zacks Investment Research restated a “sell” rating on shares of Xencor in a report on Saturday, January 13th. Finally, Wedbush raised their target price on shares of Xencor from $38.00 to $39.00 and gave the stock an “outperform” rating in a report on Monday, March 19th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $36.75.

How to Become a New Pot Stock Millionaire

The company has a market capitalization of $1,682.29, a price-to-earnings ratio of -29.27 and a beta of 1.50.

In related news, insider Paul A. Foster sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.01, for a total value of $125,050.00. Following the completion of the sale, the insider now owns 7,419 shares in the company, valued at approximately $185,549.19. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Edgardo Baracchini, Jr. sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $29.64, for a total transaction of $592,800.00. Following the completion of the sale, the insider now owns 20,000 shares of the company’s stock, valued at approximately $592,800. The disclosure for this sale can be found here. In the last 90 days, insiders sold 105,000 shares of company stock valued at $3,101,550. 4.03% of the stock is owned by insiders.

Several large investors have recently modified their holdings of the stock. Nationwide Fund Advisors lifted its position in shares of Xencor by 4.5% in the 3rd quarter. Nationwide Fund Advisors now owns 62,180 shares of the biopharmaceutical company’s stock valued at $1,425,000 after acquiring an additional 2,676 shares in the last quarter. Vident Investment Advisory LLC lifted its position in shares of Xencor by 5.9% in the 4th quarter. Vident Investment Advisory LLC now owns 59,426 shares of the biopharmaceutical company’s stock valued at $1,303,000 after acquiring an additional 3,289 shares in the last quarter. Swiss National Bank lifted its position in shares of Xencor by 5.2% in the 3rd quarter. Swiss National Bank now owns 66,400 shares of the biopharmaceutical company’s stock valued at $1,522,000 after acquiring an additional 3,300 shares in the last quarter. Great West Life Assurance Co. Can lifted its position in shares of Xencor by 158.9% in the 3rd quarter. Great West Life Assurance Co. Can now owns 6,526 shares of the biopharmaceutical company’s stock valued at $150,000 after acquiring an additional 4,005 shares in the last quarter. Finally, Victory Capital Management Inc. lifted its position in shares of Xencor by 14.9% in the 4th quarter. Victory Capital Management Inc. now owns 33,954 shares of the biopharmaceutical company’s stock valued at $744,000 after acquiring an additional 4,410 shares in the last quarter. Institutional investors and hedge funds own 79.49% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was first posted by Ticker Report and is owned by of Ticker Report. If you are viewing this article on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The original version of this article can be viewed at https://www.tickerreport.com/banking-finance/3296228/xencor-xncr-shares-gap-down-to-30-98.html.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

FIG Partners Comments on Central Valley Community Bancorp’s FY2019 Earnings
FIG Partners Comments on Central Valley Community Bancorp’s FY2019 Earnings
Jupiter Fund Management’s  “Hold” Rating Reiterated at Numis Securities
Jupiter Fund Management’s “Hold” Rating Reiterated at Numis Securities
Howdens Joinery’s  “Add” Rating Reiterated at Numis Securities
Howdens Joinery’s “Add” Rating Reiterated at Numis Securities
Hammerson  Upgraded by Barclays to “Equal weight”
Hammerson Upgraded by Barclays to “Equal weight”
Liberum Capital Reiterates Hold Rating for Intu Properties
Liberum Capital Reiterates Hold Rating for Intu Properties
Peel Hunt Reaffirms “Buy” Rating for JD Sports Fashion
Peel Hunt Reaffirms “Buy” Rating for JD Sports Fashion


© 2006-2018 Ticker Report. Google+.